<unk>  moderately inhibits the liver enzyme CYP2D6. Blood plasma concentrations of the CYP2D6 substrate dextromethorphan have increased threefold when combined with<unk> ; and increased concentrations of other substrates are expected. The drug also inhibits the transporter proteins ABCG2 (breast cancer resistance protein, BCRP) and P-glycoprotein (P-gp), which has been shown to increase plasma concentrations of the ABCG2 substrate sulfasalazine twofold and the P-gp substrate digoxin by 70%. Strong inducers of the liver enzyme CYP3A4 decrease the area under the curve of<unk>  and its active metabolite (called M19); for rifampicin, this effect was almost 90% in a study. Inhibitors of CYP3A4 have no relevant effect on<unk>  concentrations.
Rolapitant
Ezlopitant
Terguride
Telmisartan
Isosorbide dinitrate
Mitapivat
Cobicistat
Eluxadoline